Disclosure notes that Eric J. Nestler, serving as a thesis adviser, is on BPGbio’s Scientific Advisory Board in a compensated role.

A first living-tissue molecular-structural map was produced by integrating living tissue data with MRI-derived measures (cortical volume, area, thickness) and multi-omics datasets.

The study used living cortical tissue from patients undergoing routine deep brain stimulation, combined with MRI and multi-omics analyses through Mount Sinai's Living Brain Project, to create a direct molecular map linking living cell biology to brain architecture.

The research signals a shift toward live human tissue, aging biology, cross-cellular integration, and causal modeling to improve drug development and therapeutic strategies.

The study is seen as advancing a new era for neurodegenerative disease research with potential partnerships to translate insights into therapies, and notes the data will be explored by BPGbio’s causal AI platform NAi.

A landmark CELL study from Mount Sinai and BPGbio reports that cellular senescence is an active, regulated program shaping human brain structure across the lifespan, challenging the view of senescence as merely passive aging.

The press release provides background on BPGbio and the Living Brain Project as context for the study’s significance and potential applications.

The CELL study also outlines a novel molecular roadmap for human brain aging, highlighting cellular senescence as an active program from development through aging.

Leaders at Mount Sinai and BPGbio stress shifting from postmortem models to living tissue and anticipate industry partnerships to translate findings into therapies.

The findings are designed to inform precision therapies for neurodegenerative diseases like Alzheimer's and Parkinson's and to accelerate translational research using living human brain biology rather than postmortem tissue.

The study positions the living human brain as a primary biological reference for therapeutic innovation and foundational for precision therapies targeting neurodegenerative diseases.

The research analyzed living cortical brain tissue from 141 neurosurgical patients, integrating MRI and multi-omics (bulk RNA sequencing, proteomics, and single-nucleus RNA sequencing) to map molecular activity to brain architecture, creating the first living-tissue molecular–structural map.